Kidney protective mechanisms of SGLT2 inhibitors: evidence for a hemodynamic effect

被引：4
|
作者：
Yau, Kevin [1 ,2 ]
Cherney, David Z. I. [1 ,2 ]
van Raalte, Daniel H. [3 ,4 ,5 ]
Wever, Britt E. [3 ,4 ]
机构：
[1] Univ Hlth Network, Dept Med, Div Nephrol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Univ Amsterdam, Diabet Ctr, Med Ctr, Dept Internal Med, Amsterdam, Netherlands
[4] Vrije Univ Univ, Res Inst Amsterdam Cardiovasc Sci, Amsterdam, Netherlands
[5] Univ Amsterdam, Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
来源：
KIDNEY INTERNATIONAL | 2024年 / 105卷 / 06期
基金：
加拿大健康研究院;
关键词：
GLUCOSE COTRANSPORTER-2 INHIBITION; GLOMERULAR-FILTRATION-RATE; TRIAL;
D O I：
10.1016/j.kint.2024.03.019
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1168 / 1172
页数：5
相关论文
共 50 条
  • [41] SGLT2 inhibitors: glucosuria as an explanation for cardiorenal protective effects?
    Simon, Annika
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 (02) : 100 - 101
  • [42] The growing clinical effect of SGLT2 inhibitors
    Del Prato, Stefano
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (04): : 218 - 219
  • [43] Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations
    Bryony Beal
    Aletta E. Schutte
    Brendon L. Neuen
    Current Hypertension Reports, 2023, 25 : 429 - 435
  • [44] Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
    Bonora, Benedetta Maria
    Avogaro, Angelo
    Fadini, Gian Paolo
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 161 - 174
  • [45] Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations
    Beal, Bryony
    Schutte, Aletta E.
    Neuen, Brendon L.
    CURRENT HYPERTENSION REPORTS, 2023, 25 (12) : 429 - 435
  • [46] SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Kanduri, Swetha R.
    Kovvuru, Karthik
    Hansrivijit, Panupong
    Thongprayoon, Charat
    Vallabhajosyula, Saraschandra
    Pivovarova, Aleksandra I.
    Chewcharat, Api
    Garla, Vishnu
    Medaura, Juan
    Cheungpasitporn, Wisit
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09)
  • [47] More Evidence for SGLT2 Inhibitors in Heart Failure
    Jarcho, John A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15): : 1481 - 1482
  • [48] Are the Protective Effects of SGLT2 Inhibitors a "Class-Effect" or Are There Differences between Agents?
    Schmidt, Darren W.
    Argyropoulos, Christos
    Singh, Namita
    KIDNEY360, 2021, 2 (05): : 881 - 885
  • [49] Mechanisms of heart failure and chronic kidney disease protection by SGLT2 inhibitors in nondiabetic conditions
    Girardi, Adriana C. C.
    Polidoro, Juliano Z.
    Castro, Paulo C.
    Pio-Abreu, Andrea
    Noronha, Irene L.
    Drager, Luciano F.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2024, 327 (03): : C525 - C544
  • [50] SGLT2 Inhibitors slow the Progression of chronic Kidney Disease
    不详
    DIABETOLOGE, 2019, 15 (06): : 567 - 567
12345